Skip to main content
. 2014 Oct 13;207(1):139–158. doi: 10.1083/jcb.201402079

Figure 10.

Figure 10.

Treatment with prednisone or VBP15 suppresses the TGF-β network in both WT asynchronous remodeling and mdx mice. Top images are mRNA profile data of skeletal muscles from a 4-mo preclinical drug trial of 5 mg/kg/d prednisone and 15 mg/kg/d VBP15. Muscle functional testing and histology on this trial has been previously published (Heier et al., 2013). The TGF-β and fibrosis pathways seen in experimental asynchronous remodeling and DMD biopsies were queried for the relative expression of mRNAs between the indicated samples, with red color indicating up-regulation (p-values underneath network members) and green color indicating down-regulation. Untreated mdx muscle shows strong up-regulation of the network (mdx vs. WT). Treatment with either prednisone (prednisone-treated mdx vs. untreated mdx) or VBP15 (VBP15-treated mdx vs. untreated mdx) shows strong suppression of this network. Bottom images show comparison of expression profiles from LCM samples of asynchronously remodeling regions of WT muscle. The cross talk region between injection sites shows up-regulation of the TGF-β fibrosis network (higher in 10 d compared with 4 d) and prednisone treatment of 4-d asynchronous remodeling mice with prednisone suppresses the network (pretreated, 4-d cross talk area vs. uninjured).